[Drug therapies following heart failure and myocardial infarction(discussion)].
Shimizu
Takeshi
T
Komuro
Issei
I
Hirayama
Haruo
H
Hiramitsu
Shinya
S
Shimizu
Kiyokazu
K
Yoshida
Osamu
O
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology / Q000627:therapeutic use; D001713:Biphenyl Compounds; D006332:Cardiomegaly / Q000188:drug therapy / Q000209:etiology; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy / Q000209:etiology; D011945:Receptors, Angiotensin; D012084:Renin-Angiotensin System / Q000502:physiology; D013314:Stress, Mechanical; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use; D020257:Ventricular Remodeling
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D011945:Receptors, Angiotensin; D013777:Tetrazoles; C081643:candesartan